• JNJ
• LLY
• SNY

Sanofi plans to change hospital drug-discount program

• AMGN
• LLY
• NVO

Analysis-Wall Street awaits Amgen weight-loss drug data expected to move shares

• LLY
• NVO
• REGN

China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug

• LLY
• MERC
• NVO

Weight-loss drug coverage rises among largest US employers, Mercer survey finds

• LLY
• NVO

Exclusive-Medicaid fuels US coverage of Novo, Lilly weight-loss drugs

U.S. government health plans dominate weight-loss drug coverage, with significant access through Medicaid, while private insurers lag, impacting healthcare costs and availability.

• BAVA
• CAG
• CCEP
• CHD
• CL
• GIS
• KDP
• KHC
• LLY
• MNST
• MRNA
• NVAX
• NVO
• PEP
• PFE
• PG
• RHHBY
• SNY

Drugmaker stocks slide as Trump taps vaccine skeptic RFK Jr for US health job

U.S. drugmaker shares fell after Trump appointed Robert F. Kennedy Jr. to lead health, raising investor concerns over vaccine policies and agency oversight.

• JNJ
• LLY

Lilly sues US agency over blocking of drug-rebate program

Eli Lilly has sued HRSA for blocking its proposed drug discount changes under the federal 340B program, which aids low-income healthcare providers.

• CTLT
• LLY
• NVO

EU regulators quiz Novo Nordisk, Catalent rivals on $16.5 billion deal

EU regulators are reviewing Novo Holdings' $16.5 billion acquisition of Catalent, seeking feedback on market competition concerns and vertical links in contract manufacturing sectors.

• ABBV
• IBB
• LLY

Trump 2.0 to be modest positive for BioPharma, BMO says, but watch FDA

BMO Capital Markets analysts predict Trump's presidency will positively impact the biopharma sector, despite concerns over potential healthcare appointees and tax policy uncertainties.

• CTLT
• LLY
• NVO

Catalent misses Q1 revenue estimates ahead of $16.5 billion deal close with Novo Holdings

Catalent reports a surprising first-quarter loss amid Novo Holdings acquisition plans, with revenue falling short of expectations, raising antitrust concerns over competition in the weight-loss drug market.